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Abstract 
There has been a massive increase in the number of large scale biological datasets during the past twenty years, producing new 
challenges and complexities for analysis. Many of these new datasets are in the 'omics fields, involving analysis of the genome,
transcriptome, and proteome among others. Here, we review 'omics community-specific factors affecting use of bioinformatics 
workflow systems. We identify the characteristics of the audience for scientific workflow systems in this community, the 
existence of a large amount of prewritten software, the use of large amounts of data in a typical analysis, and the growing 
complexity of analyses as important factors in considering workflow design criteria in this field and also future development of
Kepler. Generally, many factors favor much increased use of Kepler in bioinformatics in the future, in particular its advantages in 
comprehensibility, extensibility, and modifiability of bioinformatics pipelines. We suggest concrete steps to enable further use of 
this flexible workflow system in 'omics analyses. 
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1. Introduction 
During the past two decades, there has been an enormous explosion in the power and number of technologies for 
deriving large scale biological data on a molecular level (e.g. gene expression microarrays, next-generation 
sequencing) [1]. Within the world of molecular biology, these high throughput areas are refered to as " 'omics" as in 
genome. Just as the genome refers to all of the DNA in a cell/tissue, other 'omics terms refer to the overall set of 
components in a cell. For example, the proteome (and by extension proteomics) refers to large scale determination 
of protein abundance/identity in a cell type/tissue type. Current additional prevalent uses of omics terms include 
"metabolome" (for all metabolic products) and "transcriptome" (all RNA transcripts), among others.  
New 'omics technologies have led to new challenges for bioinformatics analyses of the resulting data sets. There 
has been a large amount of development of new bioinformatics algorithms and also of appropriate metadata 
resources (e.g. pathway analysis systems for gene expression). It has become apparent that even closely related 
platforms within an 'omics technology (e.g. Affymetrix microarrays versus Illumina microarrays for gene 
expression) require development of individualized algorithms and software tools for accurate analysis. In addition, 
* Corresponding author. Tel.: 403-210-6157; fax: 403-210-8115. 
E-mail address: mbieda@ucalgary.ca. 
Available online at www.sciencedirect.com
Open access under CC BY-NC-ND license.
1636   Mark Bieda /  Procedia Computer Science  9 ( 2012 )  1635 – 1638 
development of new technologies and new platforms is ongoing. 
Here, we focus on the needs of the 'omics community for scientific workflows. We highlight four basic factors 
that will affect development of Kepler workflows and Kepler itself for this community. First, the audience of the 
workflows must be taken into account. We argue that experienced bioinformaticians are the primary audience of the 
system, but that the great majority of end-users will have relatively few computer skills. Second, the existence of a 
large and continuously growing set of bioinformatics tools means that Kepler's ability to easily and intelligently 
integrate external tools is critical. Third, the large size of individual datasets argues for computation primarily based 
on local resources and local programs, at least for initial steps. Finally, data analyses in this area are growing 
increasingly complex, which provides clear opportunities for large growth in use of scientific workflow systems 
generally. We conclude by considering steps for the Kepler community to address these needs. 
2. Kepler in the 'omics laboratory 
2.1. Audience for Kepler in the 'omics laboratory 
Scientific workflow systems are sometimes seen as systems in which the end-user would reconfigure workflows 
or even develop de novo workflows from a library of actors. This does not fit the realities of molecular biology 
environments. Instead, usage of scientific workflow systems will currently be divided into two fundamental, and 
very different, groups. Bioinformaticians, who generally will possess good understanding of bioinformatics 
algorithms, parameter usage, and general programming, will develop actors and full workflows and, in some cases, 
also act as final end-users (performing actual data analysis). Classical molecular biologists, generally possessing 
relatively low amounts of understanding of algorithms or programming, will simply use the software under 
instruction from the bioinformatician.  
This model has important implications for use of general purpose workflow systems in the bioinformatics 
community and for the appropriate development of workflows for this community. Critically, the workflow systems 
must offer primary value to the bioinformatician; end-users treating workflows as "black box" applications may not 
see special value in the Kepler approach. The low level of computer skills of most end-users means that simplicity 
and clarity of actual workflow operation must be emphasized in Kepler development and workflow development. 
We suggest that Kepler's ability to add annotations to the workflow canvas with control over position, text font, size, 
and color offers a major advantage and should be heavily employed in 'omics workflows. 
2.2 Large existing and rapidly growing body of software 
The current phase of 'omics features both rapid introduction of new experimental platforms and great expansion 
in the number of laboratories using these technologies. Many bioinformaticians work on development of new 
primary data analysis algorithms with implementation and testing using traditional programming approaches (e.g. 
Java programming). Scientific workflow systems are sometimes viewed as environments for development of these 
primary data analysis algorithms. Under this model, actors focusing on low-level functions are important. However, 
it seems highly unlikely that Kepler will be used in this way given the bioinformatics community's long history of 
success of algorithm development using traditional approaches and the community's needs for algorithm speed and 
ease of distribution.
Currently, there are large numbers of existing software packages and many are being produced for both primary 
data analysis and secondary analysis. Importantly, many 'omics software packages offer well-written, pretested 
implementations of complex algorithms, including handling of special cases. The often-used R/BioConductor set 
features 516 packages as of 2011 [2], with nearly all aimed toward 'omics analysis. These packages typically consist 
of 10 or more modules, potentially leading to >5000 different modules, each of which could be implemented as an 
actor. Moving these ~5000 or more modules into Kepler as individual actors would currently be very time-
consuming.  Hence, the Kepler community should seek to develop approaches to automate or at least semi-automate 
the conversion of R/BioConductor packages to sets of Kepler actors. 
Given the large body of high-quality tools, the experienced bioinformatician is most interested in using existing 
programs as components in pipelines. Under these conditions, it is important that efficient creation of Kepler actors 
based on external programs is specifically supported. Intermediate tools that allow rapid, guided production of these 
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actors (perhaps based on a simple external utility) would greatly enhance use of Kepler in this community. Specific 
scientific questions often require customized 'omics pipelines. Generally, given the rapidly changing landscape of 
'omics technologies and software, there are also great needs for modifiability and extensibility of pipelines, clear 
strengths of Kepler. Finally, the intrinsically graphical nature of Kepler workflows can enable rapid comprehension 
of pipeline functionality and components, which is also favored in a situation with rapidly changing demands and 
potential pipeline components. 
2.3 Large data files  
Although scientific workflow systems are often phrased in terms of use of remote web services [3], this is not an 
appropriate usage model in this community. 'Omics analyses increasingly involve files (or sets of files) that are large 
in total (100s of megabytes to several gigabytes) [4]. Furthermore, total data set sizes are increasing over time, 
mostly due to increases in the size of individual data sets as high-throughput techniques increase in scale. Moving 
these large sets of data from one web service to another is slow and can be problematic, so use of local resources 
(local data and local programs) is heavily favored. In total, realistic workflows must rely on local resources in most 
cases.   
However, at later stages of data processing, there is often (but not always) relevant and significant data reduction. 
For example, a large ChIP-seq (chromatin immunoprecipitation followed by sequencing) dataset is usually reduced 
to a much smaller dataset of binding site locations in the genome. Use of remote web services for the later 
processing stages is reasonable and appropriate. In particular, use of remote data annotation resources may be 
beneficial.  
2.4 Data analyses are growing increasingly complex 
The increasing size of the 'omics world has led to a large increase in demands on bioinformatics analyses. To 
begin, analyses often involve multiple data types. For example, ChIP-seq data is often combined with gene 
expression data to gain insight into functions of transcription factors. Second, the existence of different platforms 
aimed at the same type of data (e.g. different formats of gene expression microarrays) means that cross-platform 
analysis pipelines must be developed. Third, the development of high quality metadata resources and new types of 
resources (e.g. gene pathway resources) produces demands for more complex, better metadata analyses [5]. Finally, 
the existence of large, well-described and publically available archives of data (e.g. [6]) has led to increasing interest 
in meta-analyses of already published data. 
 In an environment of small scale and relatively simple analyses, scientific workflow systems are more of a 
luxury than a necessity. However, just over the past two years, bioinformatics analyses have reached a size and 
complexity at which the attributes of scientific workflow systems are now requirements instead of attractive options. 
Hence, there is a current opportunity for Kepler to play a much larger role in the bioinformatics community.  Of 
special note is that bioinformatics analyses are already parameter-rich. The ability of Kepler, in particular, to 
provide a clear representation of parameters on the workflow canvas will be increasingly valued under these 
conditions of increasingly complex analyses. 
2.5. Two paths forward for use of Kepler in the laboratory 
How can Kepler play a larger role in the complex ecosystem of bioinformatics tools? The disadvantages of 
Kepler should not be underestimated, in that there can be a significant learning stage and the concepts underlying 
the Kepler model will not be familiar to most bioinformaticists. As bioinformatics analyses become more complex, 
Kepler (or other similar systems) has the promise of providing robust solutions to difficult problems. 
There are two clear potential models to ease Kepler acceptance in the world of bioinformatics. First, the 
construction of specific 'omics workflows and actors - especially those embodying the most used tools in the field - 
may be critical for adoption of Kepler in this community.  Second, development of "unique" workflows in the 
Kepler system would stimulate usage. We suggest that these workflows should focus upon poorly addressed issues 
in bioinformatics or areas that have attracted less attention than mammalian genomics (e.g. proteomic analyses). 
Two other approaches are useful but less impactful. Large workflows that embody complex analyses can serve as 
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easy demonstrations of the power of the Kepler model and should in themselves be useful (e.g. WATERS for 
metagenomics [7]). Finally, production of workflows within Kepler that use existing algorithms but provide 
important functionality addressing critical current issues will induce some usage. For example, workflows 
combining data types would be very attractive to some bioinformaticians.  
3. Conclusions 
We suggest that the nature of bioinformatics analyses places certain constraints on development of Kepler 
workflows and the probable use of Kepler in bioinformatics contexts. First, bioinformatics workflows should 
emphasize use of local resources (data, programs) particularly for the first stages of computation. This follows from 
the large size of primary data files and the fact that many bioinformatics applications are not available as web 
services. However, for secondary analysis when files are smaller, development of a library of actors for connecting 
to popular bioinformatics web services, especially those concerned with annotation (metadata) issues, should be 
emphasized. Second, because bioinformaticians will control adoption of this system in 'omics fields, ease of 
development of workflows focusing primarily on external programs should be emphasized. In particular, special 
provision should be made to ensure that R/BioConductor workflows can be easily developed in the Kepler 
framework. For example, R/BioConductor syntax highlighting and rapid R/BioConductor actor testing would be 
advantageous in future Kepler versions. Third, because most end-users will be classical molecular biologists with 
few computer skills, continued development of graphical aspects of Kepler is a priority for this community. Changes 
should be user-tested. Fourth, 'omics workflow design should take advantage of Kepler's abilities to promote 
extensibility, modifiability, and comprehensibility of workflows. In particular, the ability of Kepler to organize 
parameters on the workflow canvas should be emphasized. 'omics is growing and bioinformatics education is 
becoming more standardized and widespread, so comprehensibility will become more important as more users 
desire deeper understanding of bioinformatics pipelines. Finally, due to this community's use of mostly external 
applications that produce data files as output, data provenance for 'omics workflows should develop a focus on 
tracking external files and use a format designed for bioinformatician accessibility. 
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